Sekwon Jang

1.6k total citations
42 papers, 724 citations indexed

About

Sekwon Jang is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Sekwon Jang has authored 42 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 10 papers in Immunology and 9 papers in Molecular Biology. Recurrent topics in Sekwon Jang's work include Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (9 papers) and Immunotherapy and Immune Responses (7 papers). Sekwon Jang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (9 papers) and Immunotherapy and Immune Responses (7 papers). Sekwon Jang collaborates with scholars based in United States, Australia and United Kingdom. Sekwon Jang's co-authors include Michael B. Atkins, Navneet S. Majhail, Henri Roukoz, Amer Beitinjaneh, Suraj Venna, Tufia C. Haddad, Young Kwang Chae, Anna E. Prizment, Kim Robien and Michael B. Atkins and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Sekwon Jang

37 papers receiving 715 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sekwon Jang United States 14 402 269 161 132 109 42 724
Sachin Shah United States 13 286 0.7× 211 0.8× 68 0.4× 103 0.8× 172 1.6× 25 737
Florence Broussais France 14 350 0.9× 347 1.3× 267 1.7× 216 1.6× 85 0.8× 25 952
James E. Ward United States 12 360 0.9× 340 1.3× 63 0.4× 269 2.0× 100 0.9× 16 730
Shruti Agrawal India 12 447 1.1× 120 0.4× 137 0.9× 109 0.8× 235 2.2× 33 726
Masoud Davanlou United States 4 536 1.3× 312 1.2× 290 1.8× 320 2.4× 108 1.0× 7 1.1k
Donald C. Moore United States 13 276 0.7× 206 0.8× 90 0.6× 144 1.1× 141 1.3× 80 750
Jill Kolesar United States 19 329 0.8× 296 1.1× 132 0.8× 55 0.4× 139 1.3× 68 948
Jonathon Vallejo United States 12 309 0.8× 86 0.3× 77 0.5× 84 0.6× 152 1.4× 31 530
Rosa Giuliani Italy 15 524 1.3× 166 0.6× 127 0.8× 60 0.5× 128 1.2× 31 805
Mustaqeem Siddiqui United States 12 216 0.5× 152 0.6× 71 0.4× 80 0.6× 47 0.4× 39 603

Countries citing papers authored by Sekwon Jang

Since Specialization
Citations

This map shows the geographic impact of Sekwon Jang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sekwon Jang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sekwon Jang more than expected).

Fields of papers citing papers by Sekwon Jang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sekwon Jang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sekwon Jang. The network helps show where Sekwon Jang may publish in the future.

Co-authorship network of co-authors of Sekwon Jang

This figure shows the co-authorship network connecting the top 25 collaborators of Sekwon Jang. A scholar is included among the top collaborators of Sekwon Jang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sekwon Jang. Sekwon Jang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dummer, Reinhard, Jean‐Jacques Grob, Caroline Robert, et al.. (2024). Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.. Journal of Clinical Oncology. 42(16_suppl). 9506–9506. 2 indexed citations
2.
Venna, Suraj, et al.. (2024). Merkel cell carcinoma. Journal of the American Academy of Dermatology. 91(3). 598–605. 1 indexed citations
3.
Belzberg, Micah, et al.. (2024). Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatlimab. The Oncologist. 29(12). e1783–e1785. 1 indexed citations
4.
Kirkwood, John M., Lisa A. Kottschade, Robert R. McWilliams, et al.. (2023). Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study. Immunotherapy. 16(1). 29–42. 3 indexed citations
5.
6.
Venna, Suraj, et al.. (2023). Detection of ctDNA in patients with stage III cutaneous melanoma with satellite/in-transit or nodal metastases.. Journal of Clinical Oncology. 41(16_suppl). e21559–e21559.
7.
Jang, Sekwon, et al.. (2022). Brentuximab-induced hand-foot syndrome in a patient with cutaneous T-cell lymphoma. JAAD Case Reports. 21. 123–125.
8.
Abbott, Charles W., Sean M. Boyle, Rachel Marty Pyke, et al.. (2021). Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms. Clinical Cancer Research. 27(15). 4265–4276. 35 indexed citations
9.
Jang, Sekwon, et al.. (2020). Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma. Dermatology and Therapy. 10(5). 985–999. 12 indexed citations
10.
Kaufman, Bridget, Elizabeth M. Dugan, Arash Radfar, et al.. (2020). Importance of pathology review to complement clinical management of melanoma. Journal of the American Academy of Dermatology. 83(6). 1784–1786. 1 indexed citations
11.
Wang, Hongkun, et al.. (2020). Five-year survival in patients with nodular and superficial spreading melanomas in the US population. Journal of the American Academy of Dermatology. 84(4). 1015–1022. 30 indexed citations
12.
Jang, Sekwon, et al.. (2018). Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. Journal for ImmunoTherapy of Cancer. 6(1). 49–49. 95 indexed citations
13.
Jang, Sekwon, Andrea K. Finlay, Jennifer DeSimone, et al.. (2016). Early discussion of advance directives for patients with newly diagnosed cancer.. Journal of Clinical Oncology. 34(7_suppl). 91–91. 2 indexed citations
14.
Ranpura, Vishal, Sundeep Agrawal, Charan Yerasi, et al.. (2015). Improving Documentation of Pain Management at MedStar Washington Cancer Institute. Journal of Oncology Practice. 11(2). 155–157. 11 indexed citations
15.
Pichard, Dominique C., et al.. (2013). Vemurafenib-Induced DRESS. JAMA Dermatology. 149(10). 1242–1242. 27 indexed citations
16.
Jang, Sekwon & Michael B. Atkins. (2013). Which drug, and when, for patients with BRAF-mutant melanoma?. The Lancet Oncology. 14(2). e60–e69. 133 indexed citations
17.
Jang, Sekwon, Anna E. Prizment, Tufia C. Haddad, Kim Robien, & DeAnn Lazovich. (2010). Smoking and quality of life among female survivors of breast, colorectal and endometrial cancers in a prospective cohort study. Journal of Cancer Survivorship. 5(2). 115–122. 43 indexed citations
18.
Beitinjaneh, Amer, Sekwon Jang, Henri Roukoz, & Navneet S. Majhail. (2010). Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: A systematic review. Leukemia Research. 34(7). 831–836. 65 indexed citations
19.
Jang, Sekwon, Young Kwang Chae, & Navneet S. Majhail. (2010). Financial Conflicts of Interest in Economic Analyses in Oncology. American Journal of Clinical Oncology. 34(5). 524–528. 13 indexed citations
20.
Chun, Byung Chul, June‐Young Lee, Sekwon Jang, et al.. (2003). The Selection of the Most Painful Word in the Visual Analogue Scale(VAS) for Pain and the Psychosocial Factors in Association with Pain Assessment in Korean Adult Cancer Patients - for the Development of Korean Cancer Pain Assessment Tool(K-CPAT) by Delphi Method -. The Korean Journal of Hospice and Palliative Care. 6(1). 11–21. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sachin Shah Breakdown of academic impact, for papers by Florence Broussais Breakdown of academic impact, for papers by James E. Ward Breakdown of academic impact, for papers by Shruti Agrawal Breakdown of academic impact, for papers by Masoud Davanlou Breakdown of academic impact, for papers by Donald C. Moore Breakdown of academic impact, for papers by Jill Kolesar Breakdown of academic impact, for papers by Jonathon Vallejo Breakdown of academic impact, for papers by Rosa Giuliani Breakdown of academic impact, for papers by Mustaqeem Siddiqui
Rankless by CCL
2026